• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Theses
  • Research Data
  • Projects
  • Organizations
  • Researchers
  • More
  • Collections
  • Statistics
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Controversy Over Liver Transplantation or Resection for Neuroendocrine Liver Metastasis: Tumor Biology Cuts the Deal.
 

Controversy Over Liver Transplantation or Resection for Neuroendocrine Liver Metastasis: Tumor Biology Cuts the Deal.

Options
  • Details
  • Files
BORIS DOI
10.48350/172154
Publisher DOI
10.1097/SLA.0000000000005663
PubMed ID
35975918
Description
BACKGROUND

In patients with neuroendocrine liver metastasis (NELM), liver transplantation (LT) is an alternative to liver resection (LR), although the choice of therapy remains controversial. In this multicenter study we aim to provide novel insight in this dispute.

METHODS

Following a systematic literature search, 15 large international centers were contacted to provide comprehensive data on their patients after LR or LT for NELM. Survival analyses were performed with the Kaplan-Meier method, while multivariable Cox regression served to identify factors influencing survival after either transplantation or resection. Inverse probability weighting (IPW) and propensity score matching was used for analyses with balanced and equalized baseline characteristics.

RESULTS

Overall, 455 patients were analyzed, including 230 after LR and 225 after LT, with a median follow-up of 97 (95% CI 85-110) months. Multivariable analysis revealed G3 grading as a negative prognostic factor for LR (HR 2.22, 95%CI 1.04-4.77, P=0.040), while G2 grading (HR 2.52, 95%CI 1.15-5.52, P=0.021) and LT outside Milan criteria (HR 2.40, 95%CI 1.16-4.92, P=0.018) were negative prognostic factors in transplanted patients. IP-weighted multivariate analyses revealed a distinct survival benefit after LT. Matched patients presented a median overall survival (OS) of 197 months (95%CI 143- not reached) and a 73% 5-year OS after LT, and 119 months (95%CI 74-133) and a 52.8% 5-year OS after LR (HR 0.59, 95% CI 0.3- 0.9, P=0.022). However, the survival benefit after LT was lost if patients were transplanted outside Milan criteria.

CONCLUSION

This multicentric study in patients with NELM demonstrates a survival benefit of LT over LR. This benefit depends on adherence to selection criteria, in particular low-grade tumor biology and Milan criteria, and must be balanced against potential risks of LT.
Date of Publication
2023-05-01
Publication Type
Article
Subject(s)
500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health
Language(s)
en
Contributor(s)
Eshmuminov, Dilmurodjon
Studer, Debora J
Lopez Lopez, Victor
Schneider, Marcel André
Lerut, Jan
Lo, Mary
Sher, Linda
Musholt, Thomas Johannes
Lozan, Oana
Bouzakri, Nabila
Sposito, Carlo
Miceli, Rosalba
Barat, Shoma
Morris, David
Oehler, Helga
Schreckenbach, Teresa
Husen, Peri
Rosen, Charles B
Gores, Gregory J
Masui, Toshihiko
Cheung, Tan-To
Kim-Fuchs, Corina
Universitätsklinik für Viszerale Chirurgie und Medizin, Viszeral- und Transplantationschirurgie
Perren, Aurelorcid-logo
Institut für Pathologie
Dutkowski, Philipp
Petrowsky, Henrik
Thiis-Evensen, Espen
Line, Pål-Dag
Grat, Michal
Partelli, Stefano
Falconi, Massimo
Tanno, Lulu
Robles-Campos, Ricardo
Mazzaferro, Vincenzo
Clavien, Pierre-Alain
Lehmann, Kuno
Additional Credits
Institut für Pathologie
Universitätsklinik für Viszerale Chirurgie und Medizin, Viszeral- und Transplantationschirurgie
Series
Annals of surgery
Publisher
Wolters Kluwer Health
ISSN
1528-1140
Access(Rights)
open.access
Show full item
BORIS Portal
Bern Open Repository and Information System
Build: dd892c [ 9.04. 8:30]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
  • Audiovisual Material
  • Software & other digital items
  • Events
More
  • About BORIS Portal
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo